Skip to Content
Authors Wells JT, Lucey MR, Said A
Author Profile(s)
Journal Clin Liver Dis Volume: 10 Issue: 4 Pages: 901-17
Publish Date 2006 Nov
PubMed ID 17164124

Hepatitis C virus (HCV) infection is prevalent in candidates for, and recipients of, solid organ transplants. HCV infection can lead to diminished patient and allograft survival in the long-term in recipients of kidney transplants. Outcomes in recipients of other solid organ transplants (lung, heart, small bowel, pancreas, pancreas-kidney) are not well established. Large, well-designed, prospective studies are needed to answer these questions. Interferon therapy for HCV before transplantation can lead to improved outcomes. Therefore, transplant candidates should be considered for and offered interferon therapy before embarking on organ transplantation. Posttransplant interferon therapy can be complicated by acute allograft rejection and is not recommended, except with advanced liver disease. Copyright © 2017 The Board of Regents of the University of Wisconsin System